Get the Stockscreener App
21.17
10.09%
1.94
Scribe Therapeutics Inc. Common Stock stock is traded at $21.17, with a volume of 397.08K.
It is up +10.09% in the last 24 hours and down -28.82% over the past month.
See More
Previous Close:
$19.23
Open:
$19.21
24h Volume:
397.08K
Relative Volume:
0.66
Market Cap:
$400.78M
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
+30.60%
1M Performance:
-28.82%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$15.37
$21.33
52-Week Range:
$13.50
$39.60
Scribe Therapeutics Inc. Common Stock Stock (SCTX) Company Profile
Name
Scribe Therapeutics Inc. Common Stock
Sector
Industry
Phone
-
Address
-
Compare SCTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCTX
Scribe Therapeutics Inc. Common Stock
|
21.17 | 400.78M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
510.05 | 129.28B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.32 | 85.56B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
765.11 | 78.77B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.60 | 51.35B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
190.95 | 40.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scribe Therapeutics Inc. Common Stock Stock (SCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-26 | Initiated | H.C. Wainwright | Buy |
| Aug-18-26 | Initiated | Guggenheim | Buy |
| Aug-18-26 | Initiated | Leerink Partners | Outperform |
| Aug-18-26 | Initiated | Wells Fargo | Overweight |
Scribe Therapeutics Inc. Common Stock Stock (SCTX) Latest News
Scribe Therapeutics Inc. Common Stock (NASDAQ: SCTX) Stock Price, News & Analysis - kalkine.ca
Scribe Therapeutics Inc. Common Stock (NASDAQ: SCTX) Stock Price, News & Analysis - Kalkine
Scribe Therapeutics (SCTX) awards 14,725 stock options to director Bleharski - Stock Titan
OrbiMed Advisors Discloses Investment in Scribe Therapeutics with 7.2% Stake - TradingView
Scribe Therapeutics Completes Initial Public Offering and Private Placement - SynBioBeta
Scribe Therapeutics raises $155.51M in IPO on Nasdaq By Investing.com - Investing.com India
Avoro lifts Scribe (NASDAQ: SCTX) stake to 3.09M shares - Stock Titan
Latham Advises on Scribe Therapeutics’ US$155.51 Million IPO - Legal Desire
Latham Advises on Scribe Therapeutics’ US$155.51 Million IPO - Latham & Watkins LLP
Scribe Therapeutics IPO closes as Sanofi buys 500K shares - Stock Titan
Scribe Therapeutics, In Vivo CRISPR Genetic Medicines, Files for Nasdaq IPO - TradingView
Scribe Therapeutics Announces Closing of Initial Public - GlobeNewswire
Scribe Therapeutics Closes Upsized $155.5 Million IPO and Concurrent Private Placement with Sanofi - Quiver Quantitative
Scribe Therapeutics closes $155.5M IPO at $15 per share - Investing.com
Scribe Therapeutics raises $155.51M in IPO on Nasdaq - Investing.com
Scribe Therapeutics raises $155.51M in IPO on Nasdaq By Investing.com - Investing.com Nigeria
Scribe Therapeutics (SCTX) CFO gets major option grants and family share buys - Stock Titan
Scribe Therapeutics (SCTX) awards 14,725 stock options to director James Dean Watson - Stock Titan
Scribe Therapeutics (SCTX) grants 14,725 options to Aghazadeh and Avoro entities - Stock Titan
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement - Yahoo Finance
Scribe Therapeutics (SCTX) CEO receives time- and performance-based option grants - Stock Titan
Scribe Therapeutics prices IPO at $15 per share on Nasdaq By Investing.com - Investing.com UK
IPO calendar for: - Yahoo Finance Singapore
Scribe Therapeutics prices IPO at $15 per share on Nasdaq By Investing.com - Investing.com Nigeria
Scribe Therapeutics Prices Upsized $128.7 Million Initial Public Offering and Concurrent Private Placement to Sanofi - quiverquant.com
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech - BioSpace
Scribe Therapeutics Inc. (SCTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Scribe Therapeutics (Nasdaq:SCTX)Stock Analysis - Simply Wall Street
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire
Scribe Therapeutics prices IPO at $15 per share on Nasdaq - Investing.com
Scribe Therapeutics Inc. has completed an IPO in the amount of $128.7 million. - marketscreener.com
Scribe Therapeutics prices IPO at $15, to raise $128.7M - Investing.com
Sanofi Agrees to Buy 500,000 Scribe Shares in a Private Placement - Stock Titan
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering - Yahoo Finance
Scribe Therapeutics Starts IPO Effort For CRISPR Pipeline Development (SCTX) - Seeking Alpha
Scribe Therapeutics files for 7.15M share IPO at $13-$15/sh - Investing.com
Scribe Therapeutics files for 7.15M share IPO at $13-$15/sh - Investing.com Nigeria
Scribe Therapeutics files for 7.15M share IPO at $13-$15/sh - Investing.com UK
Scribe Therapeutics Inc. Common Stock Stock (SCTX) Financials Data
There is no financial data for Scribe Therapeutics Inc. Common Stock (SCTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Scribe Therapeutics Inc. Common Stock Stock (SCTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Aghazadeh Behzad | Director |
Jul 28 '26 |
Buy |
18.25 |
7,905 |
144,266 |
3,088,888 |
| GORDON CARL L | Director |
Jul 27 '26 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,348,825 |
| ORBIMED ADVISORS LLC | Director |
Jul 27 '26 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,348,825 |
| Aghazadeh Behzad | Director |
Jul 24 '26 |
Buy |
15.15 |
2,383,333 |
36,115,495 |
3,080,983 |
| Lucas Svetlana | Chief Business Officer |
Jul 23 '26 |
Buy |
15.00 |
3,000 |
45,000 |
3,000 |
| Parrot David | Chief Financial Officer |
Jul 23 '26 |
Buy |
15.00 |
2,666 |
39,990 |
1,333 |
1.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):